

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008  
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000  
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent number searching  
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing enhanced  
NEWS 6 OCT 22 WPIDS, WPIDEX, and WPIX enhanced with Canadian PCT Applications  
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of pre-registered REACH substances  
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present  
NEWS 9 NOV 26 MARPAT enhanced with FSORT command  
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts availability of new fully-indexed citations  
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy  
NEWS 12 NOV 26 Two new SET commands increase convenience of STN searching  
NEWS 13 DEC 01 ChemPort single article sales feature unavailable  
NEWS 14 DEC 12 GBFULL now offers single source for full-text coverage of complete UK patent families  
NEWS 15 DEC 17 Fifty-one pharmaceutical ingredients added to PS

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* \* \* \* STN Columbus \* \* \* \* \* \* \* \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:27:17 ON 24 DEC 2008

=> fil reg

COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE  
ENTRY  
0.21  
TOTAL  
SESSION  
0.21

FILE 'REGISTRY' ENTERED AT 13:27:28 ON 24 DEC 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 DEC 2008 HIGHEST RN 1089286-03-2  
DICTIONARY FILE UPDATES: 23 DEC 2008 HIGHEST RN 1089286-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\STNEXP\Queries\10590542.str




chain nodes :  
7 8 16 20 21 22  
ring nodes :  
1 2 3 4 5 6 10 11 12 13 14 15  
chain bonds :  
3-7 7-8 8-20 13-16 20-21 20-22  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15  
exact/norm bonds :  
7-8 8-20 13-16 20-21  
exact bonds :  
3-7 20-22  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15  
isolated ring systems :  
containing 1 : 10 :

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:Atom 20:CLASS 21:CLASS 22:Atom  
Generic attributes :  
22:  
Saturation : Saturated  
Number of Carbon Atoms : less than 7  
Type of Ring System : Monocyclic

L1 STRUCTURE UPLOADED

=> d 11  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11  
SAMPLE SEARCH INITIATED 13:27:49 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 14552 TO ITERATE

13.7% PROCESSED 2000 ITERATIONS 1 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 283813 TO 298267  
PROJECTED ANSWERS: 1 TO 306

L2 1 SEA SSS SAM L1

=> s 11 sss full  
FULL SEARCH INITIATED 13:27:55 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 291038 TO ITERATE

100.0% PROCESSED 291038 ITERATIONS  
SEARCH TIME: 00.00.15


176 ANSWERS

L3 176 SEA SSS FUL L1

=> d scan

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 1H-Imidazole-5-carboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-1-methyl-  
MF C24 H24 C12 F N5 O3

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 2-Pyrazinecarboxamide, 6-chloro-N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-  
MF C24 H19 C13 F3 N5 O3

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]-  
 MF C21 H19 Cl2 F4 N3 O3

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 5-Thiazolecarboxamide, N-[[[1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]-  
 MF C23 H19 Cl2 F3 N4 O3 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-  
 MF C21 H20 Cl2 F3 N3 O3


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Cyclopropanecarboxamide, 1-(1,3-benzodioxol-5-yl)-N-[5-(2-methoxyphenyl)-4-methyl-2-pyridinyl]-  
 MF C24 H22 N2 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 1,2,3-Thiadiazole-4-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-  
 MF C22 H20 Cl2 F N5 O3 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 5-isoxazolecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-3-methoxy-  
 MF C24 H21 Cl2 F3 N4 O5


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Cyclopropanecarboxamide, 1-(1,3-benzodioxol-5-yl)-N-[5-(2,6-dimethoxyphenyl)-2-pyridinyl]-  
 MF C24 H22 N2 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-  
 MF C21 H22 Cl2 F N3 O3

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 5-Isoazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]-  
 MF C23 H19 Cl3 F2 N4 O4


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN Cyclopropanecarboxamide, 1-(1,3-benzodioxol-5-yl)-N-[6-(5-fluoro-2-methoxyphenyl)-2-pyridinyl]-  
 MF C23 H19 F N2 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 2-Pyrazinecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]-  
 MF C24 H22 Cl2 F N5 O3

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

|                      |  |            |         |
|----------------------|--|------------|---------|
| => fil cap           |  | SINCE FILE | TOTAL   |
| COST IN U.S. DOLLARS |  | ENTRY      | SESSION |
| FULL ESTIMATED COST  |  | 178.82     | 179.03  |

FILE 'CAPLUS' ENTERED AT 13:28:47 ON 24 DEC 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Dec 2008 VOL 149 ISS 26  
FILE LAST UPDATED: 23 Dec 2008 (20081223/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 13:27:17 ON 24 DEC 2008)

FILE 'REGISTRY' ENTERED AT 13:27:28 ON 24 DEC 2008

L1                   STRUCTURE UPLOADED  
L2                   1 S L1  
L3                   176 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:28:47 ON 24 DEC 2008

=> s 13  
L4                   12 L3

=> s 13 and (pry<2005)  
                     12 L3  
                     4595104 PRY<2005  
L5                   7 L3 AND (PRY<2005)


=> d 1-7 ibib abs hitstr

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 20081174539 CAPLUS  
DOCUMENT NUMBER: 149:402214  
TITLE: Preparation of pyridine carboxamides as serine  
protease inhibitors for treating thromboembolic and  
inflammatory disorders  
INVENTOR(S): Corte, James R.; Hangeland, Jon J.; Quan, Mimi L.;  
Smallheer, Joanne M.; Fang, Tianan  
PATENT ASSIGNEE(S): Bristol Myers Squibb Company, USA  
SOURCE: U.S., 172pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

| PATENT NO. | KIND | DATE     | APPLICATION NO. | DATE        |
|------------|------|----------|-----------------|-------------|
| US 7429604 | B2   | 20080930 | US 2005-151627  | 20050613 <- |

|   |    |          |                  |                |
|---|----|----------|------------------|----------------|
| US 20060009455  | A1 | 20060112 |                  |                |
| AU 2005255029   | A1 | 20051229 | AU 2005-255029   | 20050614 <--   |
| WO 2005123680   | A1 | 20051229 | WO 2005-US20971  | 20050614 <--   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,<br>GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,<br>LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA,<br>NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,<br>SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,<br>ZA, ZM, ZW |    |          |                  |                |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,<br>AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,<br>EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,<br>RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,<br>MR, NE, SN, TD, TG  |    |          |                  |                |
| EP 1773775  | A1 | 20070418 | EP 2005-787697   | 20050614 <--   |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,<br>IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV,<br>MK, YU   |    |          |                  |                |
| CN 101010299  | A  | 20070801 | CN 2005-80027485 | 20050614 <--   |
| JP 2008502692   | T  | 20080131 | JP 2007-516646   | 20050614 <--   |
| MX 2006PA14799  | A  | 20070216 | MX 2006-PA14799  | 20061215 <--   |
| NO 2007000201   | A  | 20070312 | NO 2007-201      | 20070111 <--   |
| KR 2007022867   | A  | 20070227 | KR 2007-700830   | 20070112 <--   |
| PRIORITY APPLN. INFO.:  |    |          | US 2004-579637P  | P 20040615 <-- |
|   |    |          | US 2005-683838P  | P 20050524     |
|   |    |          | US 2005-151627   | A 20050613     |
|   |    |          | WO 2005-US20971  | W 20050614     |

OTHER SOURCE(S): MARPAT 149:402214  
GI




AB Title compds. [I; A = (substituted) cycloalkyl, cycloalkenyl, Ph, naphthyl, heterocyclyl; X1-X4 = CR3, CR4, NR6, NO, CO;  $\geq 1$  of X1-X4 = CR3; X5 = N, NR6, NO; Z = CHR11, NR13; L = CONR10, CH2CONR10, CH2NR10CO, etc.; R3 = (CH2)rCONR8R9, Q(CH2)r, etc.; r = 0-4; Q = (substituted) Ph, heterocyclyl; R4 = H, O, F, Cl, Br, iodo, OCF3, CF3, cyano, NO2, CONR8R9, etc.; R6 = H, alkyl, haloalkyl, (substituted) Ph(CH2)r, etc.; R8 = H, (substituted) alkyl, Q(CH2)n; n = 0-4; R9 = H, (substituted) Ph(CH2)n; R10 = H, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl(alkyl), etc.; R11 = haloalkyl, (CH2)rCONR8R9, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, etc.; R13 = H, (substituted) alkyl, Q(CH2)n, acyl, etc.], were prepared. Thus, 2-phenyl-1-(4-phenylpyridin-2-yl)ethanamine·2TFA (preparation given) in DMF at 0° was treated sequentially with Hunig's base, Boc-tranexamic acid, HOBt, and EDCI followed by warming to room temperature to give coupling product which was treated with CF3CO2H in CH2Cl2 to

give 4-aminomethylcyclohexanecarboxylic acid [2-phenyl-1-(4-phenylpyridin-2-yl)ethyl]amide bistrifluoroacetate. The compds. of Formula I are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. This invention also relates to pharmaceutical compns. comprising these compds. and methods of treating thromboembolic and/or inflammatory disorders using the same. Preferred I inhibited Factor XIa

with  $K_i \leq 15 \mu\text{M}$ .  
IT 872458-93-0P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(claimed compound; preparation of pyridine carboxamides as serine protease inhibitors for treating thromboembolic and inflammatory disorders)  
RN 872458-93-0 CAPLUS  
CN Cyclohexanecarboxamide, 4-(aminomethyl)-N-[1-[4-(2-methoxyphenyl)-2-pyridinyl]-2-phenylethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2005:1351066 CAPLUS  
DOCUMENT NUMBER: 144:88174  
TITLE: Preparation of pyridine carboxamides as serine protease inhibitors  
INVENTOR(S): Corte, James; Hangeland, Jon; Quan, Mimi; Smallheer, Joanne M.; Fang, Tianan  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
SOURCE: PCT Int. Appl., 243 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE         |
|---|------|----------|-----------------|--------------|
| WO 2005123680   | A1   | 20051229 | WO 2005-US20971 | 20050614 <-- |
| W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,<br>GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,<br>LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,<br>NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,<br>SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,<br>ZA, ZM, ZW |      |          |                 |              |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,<br>AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,<br>EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,<br>RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,<br>MR, NE, SN, TD, TG  |      |          |                 |              |
| US 7429604  | B2   | 20080930 | US 2005-151627  | 20050613 <-- |
| US 20060009455  | A1   | 20060112 |                 |              |
| AU 2005255029   | A1   | 20051229 | AU 2005-255029  | 20050614 <-- |
| EP 1773775  | A1   | 20070418 | EP 2005-787697  | 20050614 <-- |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,<br>IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV,   |      |          |                 |              |

|                        |   |          |                  |                |
|------------------------|---|----------|------------------|----------------|
| MK, YU                 |   |          |                  |                |
| CN 101010299           | A | 20070801 | CN 2005-80027485 | 20050614 <--   |
| JP 2008502692          | T | 20080131 | JP 2007-516646   | 20050614 <--   |
| IN 2006DN07496         | A | 20070817 | IN 2006-DN7496   | 20061212 <--   |
| MX 2006PA14799         | A | 20070216 | MX 2006-PA14799  | 20061215 <--   |
| NO 2007000201          | A | 20070312 | NO 2007-201      | 20070111 <--   |
| KR 2007022867          | A | 20070227 | KR 2007-700830   | 20070112 <--   |
| PRIORITY APPLN. INFO.: |   |          | US 2004-579637P  | P 20040615 <-- |
|                        |   |          | US 2005-683838P  | P 20050524     |
|                        |   |          | US 2005-151627   | A 20050613     |
|                        |   |          | WO 2005-US20971  | W 20050614     |

OTHER SOURCE(S): CASREACT 144:88174; MARPAT 144:88174  
GI



AB Title compds. [I; A = (substituted) cycloalkyl, cycloalkenyl, Ph, naphthyl, heterocyclyl; X1-X4 = CR<sub>3</sub>, CR<sub>4</sub>, NR<sub>6</sub>, NO, CO; ≥1 of X1-X4 = CR<sub>3</sub>; X5 = N, NR<sub>6</sub>, NO; Z = CHR<sub>13</sub>, NR<sub>13</sub>; L = CONR<sub>10</sub>, CH<sub>2</sub>CONR<sub>10</sub>, CH<sub>2</sub>NR<sub>10</sub>CO, etc.; R<sub>3</sub> = (CH<sub>2</sub>)<sub>r</sub>CONR<sub>8</sub>R<sub>9</sub>, Q(CH<sub>2</sub>)<sub>r</sub>, etc.; r = 0-4; Q = (substituted) Ph, heterocyclyl; R<sub>4</sub> = H, O, F, Cl, Br, iod, OCF<sub>3</sub>, CF<sub>3</sub>, cyano, NO<sub>2</sub>, CONR<sub>8</sub>R<sub>9</sub>, etc.; R<sub>6</sub> = H, alkyl, haloalkyl, (substituted) Ph(CH<sub>2</sub>)<sub>r</sub>, etc.; R<sub>8</sub> = H, (substituted) alkyl, Q(CH<sub>2</sub>)<sub>n</sub>; n = 0-4; R<sub>9</sub> = H, (substituted) Ph(CH<sub>2</sub>)<sub>n</sub>; R<sub>10</sub> = H, (substituted) alky, alkenyl, alkenynyl, carbocyclyl(alkyl), etc.; R<sub>11</sub> = haloalkyl, (CH<sub>2</sub>)<sub>r</sub>CONR<sub>8</sub>R<sub>9</sub>, (substituted) alkyl, alkenyl, alkenynyl, carbocyclyl, etc.; R<sub>13</sub> = H, (substituted) alkyl, Q(CH<sub>2</sub>)<sub>n</sub>, acyl, etc.], were prepared. Thus, 2-phenyl-1-(4-phenylpyridin-2-yl)ethanamine·2TFA (preparation given) in DMF at 0° was treated sequentially with Hunig's base, Boc-tranoxic acid, HOBt, and EDCI followed by warming to room temperature to give coupling product which was treated with CF<sub>3</sub>CO<sub>2</sub>H in CH<sub>2</sub>Cl<sub>2</sub>

to

give 4-aminomethylcyclohexanecarboxylic acid  
[2-phenyl-1-(4-phenylpyridin-2-yl)ethyl]amide bistrifluoroacetate.

Preferred I inhibited Factor XIa with K<sub>i</sub> ≤ 15 μM.

IT 872458-93-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of pyridine carboxamides as serine protease inhibitors)

RN 872458-93-0 CAPLUS

CN Cyclohexanecarboxamide, 4-(aminomethyl)-N-[1-[4-(2-methoxyphenyl)-2-pyridinyl]-2-phenylethyl]-, trans- (CA INDEX NAME)



Relative stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 20051004708 CAPLUS  
DOCUMENT NUMBER: 143:306182  
TITLE: Preparation of 1-aminocyclopropane-1-carboxamide derivatives as bradykinin B1 antagonists  
INVENTOR(S): Bock, Mark G.; Feng, Dong-Mei; Kuduk, Scott  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
SOURCE: PCT Int. Appl., 40 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO.  | DATE           |
|---|------|----------|------------------|----------------|
| WO 2005085198   | A2   | 20050915 | WO 2005-US6230   | 20050225 <--   |
| WO 2005085198   | A3   | 20051124 |                  |                |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                  |                |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                  |                |
| AU 2005219836   | A1   | 20050915 | AU 2005-219836   | 20050225 <--   |
| CA 2557858  | A1   | 20050915 | CA 2005-2557858  | 20050225 <--   |
| EP 1723143  | A2   | 20061122 | EP 2005-714101   | 20050225 <--   |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV   |      |          |                  |                |
| CN 1926136  | A    | 20070307 | CN 2005-80006734 | 20050225 <--   |
| JP 2007526311   | T    | 20070913 | JP 2007-501866   | 20050225 <--   |
| IN 2006DN05022  | A    | 20070413 | IN 2006-DN5022   | 20060831 <--   |
| PRIORITY APPLN. INFO.:  |      |          | US 2004-549379P  | P 20040302 <-- |
| OTHER SOURCE(S): GI   |      |          | WO 2005-US6230   | W 20050225     |



**AB** Title compds. I [wherein R1a, R1b, R1c = H or F; R2 = H or Cl; R3 = Cl or F; R4 = (un)substituted (cyclo)alkyl, aryl or heterocycle, or pharmaceutically acceptable salts thereof] were prepared as antagonists or inverse agonists of bradykinin receptors, especially as antagonists of bradykinin receptor B1. For instance, II was synthesized by acylation of dihydrochloride salt of the corresponding cyclopropanamine with 5-methyloxazole-3-carbonyl chloride in the presence of DIPEA. I exhibited affinity for the B1 receptor with IC<sub>50</sub> values of < 5μM. Therefore, I and their pharmaceutical compns. (examples given) are useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

**IT** 864641-38-3P 864641-40-7P 864641-42-9P

864641-44-1P

**RL:** PAC (Pharmacological activity); **SPN:** (Synthetic preparation); **THU:** (Therapeutic use); **BIOL:** (Biological study); **PREP:** (Preparation); **USES** (Uses)


(drug candidate; preparation of aminocyclopropanecarboxamide derivs. as bradykinin B1 antagonists)

**RN** 864641-38-3 CAPLUS

**CN** 3-Isoxazolecarboxamide, N-[1-[[((1R)-1-[5-(3,5-dichloro-2-(2,2-difluoroethoxy)phenyl)-3-fluoro-2-pyridinyl]ethyl)amino]carbonyl]cyclopropyl]-5-methyl-

(CA INDEX NAME)


Absolute stereochemistry.



RN 864641-40-7 CAPLUS

CN 5-Isoazolecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-3-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-42-9 CAPLUS

CN 2-Furancarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-5-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-44-1 CAPLUS

CN 2-Pyrazinecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-

difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 864641-46-3P 864641-48-5P 864641-49-6P  
864641-50-9P 864641-51-0P 864641-52-1P  
864641-53-2P 864641-54-3P 864641-55-4P  
864641-56-5P 864641-57-6P 864641-58-7P  
864641-59-8P 864641-60-1P 864641-61-2P  
864641-62-3P 864641-63-4P 864641-65-6P  
864641-66-7P 864641-68-9P 864641-69-0P  
864641-70-3P 864641-72-5P 864641-74-7P  
864641-76-9P 864641-78-1P 864641-80-5P  
864641-82-7P 864641-84-9P 864641-85-0P  
864641-86-1P 864641-88-3P 864641-90-7P  
864641-92-9P 864641-93-0P 864641-94-1P  
864641-96-3P 864641-98-5P 864642-00-2P  
864642-01-3P 864642-02-4P 864642-03-5P  
864642-05-7P 864642-06-8P 864642-08-0P  
864642-09-1P 864642-10-4P 864642-12-6P  
864642-14-8P 864642-16-0P 864642-18-2P  
864642-20-6P 864642-22-8P 864642-24-0P  
864642-25-1P 864642-26-2P 864642-27-3P  
864642-28-4P 864642-29-5P 864642-30-8P  
864642-31-9P 864642-32-0P 864642-34-2P  
864642-35-3P 864642-37-5P 864642-38-6P  
864642-39-7P 864642-41-1P 864642-43-3P  
864642-45-5P 864642-47-7P 864642-49-9P  
864642-51-3P 864642-53-5P 864642-54-6P  
864642-55-7P 864642-56-8P 864642-58-0P  
864642-60-4P 864642-62-6P 864642-64-8P  
864642-66-0P 864642-68-2P 864642-70-6P  
864642-72-8P 864642-74-0P 864642-76-2P  
864642-78-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of aminocyclopropanecarboxamide derivs. as bradykinin B1 antagonists)

RN 864641-46-3 CAPLUS

CN 5-Isoazolecarboxamide, 3-chloro-N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-48-5 CAPLUS

CN Cyclopropanecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-(2,2-difluoroethoxy)phenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-2,2-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-49-6 CAPLUS

CN 4-Pyridazinecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-50-9 CAPLUS

CN 4-Pyridazinecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-(2,2-difluoroethoxy)phenyl)-3-fluoro-2-

pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-51-0 CAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-52-1 CAPLUS

CN 5-Isoxazolecarboxamide, N-[(1R)-1-[5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]-3-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-53-2 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-3-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-54-3 CAPLUS

CN 5-Isoxazolecarboxamide, 3-chloro-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-55-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-bromo-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-56-5 CAPLUS

CN Cyclopropanecarboxamide, 1-[(2-cyanoacetyl)amino]-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-57-6 CAPLUS

CN 5-Thiazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]-2-(methoxymethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-58-7 CAPLUS


CN 2-Pyrazinecarboxamide, 6-chloro-N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-59-8 CAPLUS  
 CN 5-Thiazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864641-60-1 CAPLUS  
 CN 3-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-61-2 CAPLUS  
 CN 5-Thiazolecarboxamide, 2-chloro-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]cyclopropyl]- (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 864641-62-3 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-ethoxyphenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-methoxy-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 864641-63-4 CAPLUS

CN 5-Oxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2-methoxy-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 864641-65-6 CAPLUS

CN 5-Isothiazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-

3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-66-7 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]-3-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-68-9 CAPLUS


CN 3-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-ethoxyphenyl)-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-69-0 CAPLUS  
CN 5-Isoazolecarboxamide, N-[1-[[[1R)-1-[5-(3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]-3-ethoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-70-3 CAPLUS  
CN 1H-Pyrazole-3-carboxamide, N-[1-[[[1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-72-5 CAPLUS  
CN 5-Isoazolecarboxamide, N-[1-[[[1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]-3-ethoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-74-7 CAPLUS  
CN 5-Oxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-76-9 CAPLUS  
CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3-chloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864641-78-1 CAPLUS  
CN 2-Furancarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-80-5 CAPLUS

CN 2-Furancarboxamide, 5-bromo-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-82-7 CAPLUS

CN 5-Thiazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-2-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-84-9 CAPLUS

CN 2-Pyrazinecarboxamide, 6-chloro-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 864641-85-0 CAPLUS

CN 4-Oxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-86-1 CAPLUS

CN 3-Isoxazolecarboxamide, 5-cyclopropyl-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-88-3 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[1-oxopropyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-90-7 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[(1-[[[1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-92-9 CAPLUS

CN 3-Isoazolocarboxamide, N-[(1-[[[1R)-1-[5-[3,5-dichloro-2-(2,2-

difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-93-0 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]-4-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-94-1 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[[2-(methylsulfonyl)acetyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-96-3 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-3-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-98-5 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-5-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-00-2 CAPLUS

CN 2-Furancarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-01-3 CAPLUS

CN 2-Furancarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-02-4 CAPLUS

CN 2-Pyrazinecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]-6-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-03-5 CAPLUS

CN 3-Isoxazolecarboxamide, 5-cyclopropyl-N-[1-[(1R)-1-[5-(3,5-dichloro-2-(2,2-difluoroethoxy)phenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-05-7 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3-chloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-06-8 CAPLUS

CN 1,3,4-Oxadiazole-2-carboxamide, N-[(1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-5-

methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-08-0 CAPLUS

CN 2-Pyrazinecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-09-1 CAPLUS


CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-10-4 CAPLUS  
CN 2-Pyrrolidinocarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-oxo-, (2R)- (CA INDEX NAME)

## Absolute stereochemistry.




RN 864642-12-6 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-[1-[[{(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl}amino]carbonyl]cyclopropyl]-1-methyl- (CA INDEX NAME)

## Absolute stereochemistry.



RN 864642-14-8 CAPLUS  
CN 3-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]-  
(CA INDEX NAME)


## Absolute stereochemistry.



RN 864642-16-0 CAPLUS

CN 1,2,5-Oxadiazole-3-carboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-4-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-18-2 CAPLUS

CN 5-Oxazolecarboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-20-6 CAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-22-8 CAPLUS

CN 5-Isothiazolecarboxamide, 3,4-dichloro-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]cyclopropyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-24-0 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]cyclopropyl-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-25-1 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2,3-dihydro-3-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-26-2 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-27-3 CAPLUS

CN 1H-Tetrazole-5-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-

ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-28-4 CAPLUS

CN Cyclopropanecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2,2-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-29-5 CAPLUS

CN 1,2,3-Thiadiazole-4-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-30-8 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-ethoxyphenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-31-9 CAPLUS

CN Benzamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-32-0 CAPLUS

CN Cyclopropanecarboxamide, 1-[(2-chloro-2,2-difluoroacetyl)amino]-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-34-2 CAPLUS

CN 3-Isoxazolecarboxamide, N-[(1-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-35-3 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(1-oxobutyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-37-5 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(2-methyl-1-oxopropyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-38-6 CAPLUS


CN 5-Thiazolecarboxamide, N-[(1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-39-7 CAPLUS  
CN 3-Isoazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-41-1 CAPLUS  
CN Benzanide, 3-chloro-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864642-43-3 CAPLUS  
CN 5-Isoazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2,3-dihydro-3-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-45-5 CAPLUS

CN 2H-Tetrazole-5-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-47-7 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-49-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-(2,2-difluoroethoxy)phenyl)-3-fluoro-2-

pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-oxo-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-51-3 CAPLUS

CN 1H-Imidazole-5-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-53-5 CAPLUS

CN 2-Pyrazinecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-54-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-55-7 CAPLUS

CN 5-Thiazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-56-8 CAPLUS

CN 2H-1,2,3-Triazole-4-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-

ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-58-0 CAPLUS

CN 4-Isothiazolecarboxamide, 3,5-dichloro-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-60-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2-difluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-62-6 CAPLUS

CN 4-Oxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-64-8 CAPLUS

CN 3-Thiophenecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-66-0 CAPLUS

CN 3-Pyridazinecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-68-2 CAPLUS

CN 4-Thiazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-70-6 CAPLUS

CN 2-Thiazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-72-8 CAPLUS

CN 4-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]-3-methyl-5-(trifluoromethyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 864642-74-0 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-76-2 CAPLUS

CN 2-Furancarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-78-4 CAPLUS

CN 4H-1,2,4-Triazole-3-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 864642-89-7P 864642-91-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of aminocyclopropanecarboxamide derivs. as bradykinin B1 antagonists)

RN 864642-89-7 CAPLUS

CN Carbamic acid, [1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-91-1 CAPLUS

CN Cyclopropanecarboxamide, 1-amino-N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-, hydrochloride (1:2)  
(CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005612238 CAPLUS

DOCUMENT NUMBER: 143:133188

TITLE: Preparation of  $\alpha$ -hydroxy carboxamides, particularly N-biphenylmethyl and N-phenylpyridin-2-ylmethyl amides, as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation

INVENTOR(S): Wood, Michael R.; Anthony, Neville J.; Bock, Mark G.; Kuduk, Scott D.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
SOURCE: PCT Int. Appl., 51 pp.



DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO.  | DATE           |
|---|------|----------|------------------|----------------|
| WO 2005063690   | A1   | 20050714 | WO 2004-US42691  | 20041217 <--   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                  |                |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                  |                |
| AU 2004309357   | A1   | 20050714 | AU 2004-309357   | 20041217 <--   |
| CA 2550372  | A1   | 20050714 | CA 2004-2550372  | 20041217 <--   |
| EP 1706372  | A1   | 20061004 | EP 2004-814829   | 20041217 <--   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS   |      |          |                  |                |
| CN 1898198  | A    | 20070117 | CN 2004-80038255 | 20041217 <--   |
| BR 2004017928   | A    | 20070417 | BR 2004-17928    | 20041217 <--   |
| JP 2007520472   | T    | 20070726 | JP 2006-547200   | 20041217 <--   |
| IN 2006DN03156  | A    | 20070824 | IN 2006-DN3156   | 20060602 <--   |
| MX 2006PA07203  | A    | 20060818 | MX 2006-PA7203   | 20060621 <--   |
| KR 2006115753   | A    | 20061109 | KR 2006-712382   | 20060621 <--   |
| NO 2006003394   | A    | 20060912 | NO 2006-3394     | 20060721 <--   |
| PRIORITY APPLN. INFO.:  |      |          | US 2003-531643P  | P 20031222 <-- |
|   |      |          | US 2004-539637P  | P 20040128 <-- |
|   |      |          | US 2004-624958P  | P 20041104 <-- |
|   |      |          | WO 2004-US42691  | W 20041217 <-- |


OTHER SOURCE(S): CASREACT 143:133188; MARPAT 143:133188  
GI



AB Title compds. [I; Y = CH, N; R1 = (un)substituted Ph, 2,2-dioxo-2,1-benzisothiazolin-1-yl; R2 = H, (un)substituted alkyl, Ph, etc.; R3 = defined as R2; or R3 = OH; or R2CR3 = (un)substituted 3-7-membered carbocyclil; R4, R5 = independently H, halo/alkyl; R7 = H, halo] were prepared as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation associated with the bradykinin B1 pathway. For example, coupling of 1-hydroxycyclopropanecarboxylic acid with Me 4'-(aminomethyl)biphenyl-2-carboxylate gave amide II. I have


affinity for the B1 receptor in a radioligand assay as demonstrated by results of less than 5  $\mu$ M [sic].  
 IT 858412-84-7P 858412-88-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of N-biphenylmethyl and N-phenylpyridin-2-ylmethyl  $\alpha$ -hydroxycarboxamides as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation)  
 RN 858412-84-7 CAPLUS  
 CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 858412-88-1 CAPLUS  
 CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-(2,2-difluoroethoxy)phenyl)-3-fluoro-2-pyridinyl]ethyl]-1-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:71170 CAPLUS  
 DOCUMENT NUMBER: 142:176693  
 TITLE: Preparation of phenylpyridine derivatives as herbicides  
 INVENTOR(S): Takizawa, Eiji; Kumata, Shuji; Kiyokawa, Takahiro  
 PATENT ASSIGNEE(S): Nihon Nohyaku Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 67 pp.

DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.   | KIND   | DATE       | APPLICATION NO. | DATE           |
|--|--------|------------|-----------------|----------------|
| WO 2005007627  | A1     | 20050127   | WO 2004-JP10560 | 20040716 <--   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,<br>GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK,<br>LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,<br>NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,<br>TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |        |            |                 |                |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,<br>AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,<br>EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,<br>SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,<br>SN, TD, TG   |        |            |                 |                |
| JP 2005053902  | A      | 20050303   | JP 2004-211469  | 20040720 <--   |
| PRIORITY APPLN. INFO.:   |        |            | JP 2003-277112  | A 20030718 <-- |
| OTHER SOURCE(S):   | MARPAT | 142:176693 |                 |                |
| GI   |        |            |                 |                |



AB The title compds. I [A1 represents N:(O)p; A2 represents (CR3R3)i; R1 represents hydrogen, etc., and R2 represents hydrogen, etc., provided that R1 and R2 in combination can form a 4- to 8-membered ring containing X, carbon, nitrogen, oxygen, or sulfur; R3's may be the same or different and each represents hydrogen, etc., provided that two R3's in combination can form a 3- to 6-membered ring containing carbon, nitrogen, oxygen, or sulfur; R4's may be the same or different and each represents halogeno, etc.; R5's may be the same or different and each represents halogeno, etc., provided that two adjacent R5's can be bonded to each other to form OCF20, etc.; X represents CO, CS, or SOq (wherein q is 1 or 2); i is an integer of 0 to 2; m is an integer of 0 to 3; n is an integer of 1 to 5; and p is 0 or 1] are prepared. Thus, N-[6-(3-trifluoromethoxyphenyl)-2-pyridyl]methylcyclopropanecarboxamide was prepared by reaction of 6-(3-trifluoromethoxyphenyl)-2-pyridylmethylamine with cyclopropanecarbonyl chloride in toluene containing triethylamine. 59 Compds. of this invention at 1000 g/ha gave ≥ 90% control of Lindernia pyxidaria.


IT 833456-18-1P 833456-86-3P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylpyridine derivs. as herbicides)


RN 833456-18-1 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[2-(trifluoromethoxy)phenyl]-2-pyridinylmethyl]- (CA INDEX NAME)



RN 833456-86-3 CAPLUS

CN Cyclopropanecarboxamide, N-[4-methyl-6-[2-(trifluoromethoxy)phenyl]-2-pyridinylmethyl]- (CA INDEX NAME)



REFERENCE COUNT:

203 THERE ARE 203 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:203618 CAPLUS

DOCUMENT NUMBER: 140:253570

TITLE: Preparation of N-biaryl methylaminocycloalkanecarboxamide as bradykinin B1 antagonists

INVENTOR(S): Kuduk, Scott D.; Wood, Michael R.; Bock, Mark G.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE         |
|---------------|------|----------|-----------------|--------------|
| WO 2004019868 | A2   | 20040311 | WO 2003-US26628 | 20030825 <-- |
| WO 2004019868 | A3   | 20040429 |                 |              |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

|   |        |            |                 |                |
|---|--------|------------|-----------------|----------------|
| FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,<br>BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG |        |            |                 |                |
| CA 2495914  | A1     | 20040311   | CA 2003-2495914 | 20030825 <--   |
| AU 2003265674   | A1     | 20040319   | AU 2003-265674  | 20030825 <--   |
| BR 2003013239   | A      | 20050614   | BR 2003-13239   | 20030825 <--   |
| EP 1545538  | A2     | 20050629   | EP 2003-791763  | 20030825 <--   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  |        |            |                 |                |
| CN 1678320  | A      | 20051005   | CN 2003-820293  | 20030825 <--   |
| JP 2005537323   | T      | 20051208   | JP 2004-532994  | 20030825 <--   |
| US 20050288305  | A1     | 20051229   | US 2005-523911  | 20050208 <--   |
| US 7163951  | B2     | 20070116   |                 |                |
| IN 2005CN00256  | A      | 20070907   | IN 2005-CN256   | 20050224 <--   |
| MX 2005PA02245  | A      | 20050608   | MX 2005-PA2245  | 20050225 <--   |
| NO 200501539  | A      | 20050525   | NO 2005-1539    | 20050323 <--   |
| PRIORITY APPLN. INFO.:  |        |            | US 2002-406742P | P 20020829 <-- |
| OTHER SOURCE(S):  | MARPAT | 140:253570 | WO 2003-US26628 | W 20030825 <-- |
| GI  |        |            |                 |                |

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [Het = pyridyl, pyrimidinyl, N-oxide thereof; R1-2 = H, alkyl; R3a-3b = H, alkyl; R4a-4b = H, halo, alkyl, etc.; R5 = alkyl, cycloalkyl, alkynyl, alkenyl, etc.; R6a = alkyl, cycloalkyl, alkenyl, etc.; R6b-6c = H and not more than one of R6a-6c = heterocycle; R7a-7b = H, halo, CN, etc.; m = 0-3] are prepared For instance, 1-((pyrimidin-5-yl)carbonyl)amino)cyclobutanecarboxylic acid (preparation given) is coupled to Me 2-[2-(aminomethyl)pyrimidin-5-yl]-6-fluorobenzoate (preparation given; DMF, HOBr, EDCI, Et3N) to give II. Compds. of the invention have affinity for the bradykinin B1 receptor at less than 5  $\mu$ M. I are useful for the treatment of pain and inflammation.

IT 669066-85-7P, 1-((Trifluoromethyl)carbonyl)amino)-1-[[[5-[2-[2-fluoro-2-(fluoromethyl)ethoxy]-3-(chloro)-5-(chlorophenyl)-3-chloropyridin-2-yl]methyl]amino]carbonyl)cyclopropane 669066-86-8P, 1-((Trifluoromethyl)carbonyl)amino)-1-[[[5-[2-[2-fluoro-2-(fluoromethyl)ethoxy]-3-(chloro)-5-(chlorophenyl)-3-pyridin-2-yl]methyl]amino]carbonyl)cyclopropane 669066-87-9P, 1-((Trifluoromethyl)carbonyl)amino)-1-[[[5-[2-[(carbomethoxy)oxy]-3-(fluoro)phenyl]-3-fluoropyridin-2-yl]methyl]amino]carbonyl)cyclopropane 669067-11-2P, (R)-1-((Trifluoromethyl)carbonyl)amino)-1-[[1-[5-[2-(difluoromethoxy)-3-(fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl)cyclopropane 669067-15-6P, (R)-1-((Trifluoromethyl)carbonyl)amino)-1-[[1-[5-[2-(2,2,2-trifluoroethoxy)-3-(fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl)cyclopropane 669067-17-8P 669067-18-9P 669067-19-0P, (R)-1-((Trifluoromethyl)carbonyl)amino)-1-[[1-[5-[2-(2,2-difluoroethoxy)-3-(fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl)cyclopropane 669067-39-4P, (R)-1-((Trifluoromethyl)carbonyl)amino)-1-[[1-[5-[2-(ethoxy)-3-(fluoro)-5-(chlorophenyl)-3-fluoropyridin-2-yl]ethyl]amino]carbonyl)cyclopropane 669067-40-7P, (R)-1-((Trifluoromethyl)carbonyl)amino)-1-[[1-[5-[2-(2-fluoroethoxy)-3-(fluoro)-5-(chlorophenyl)-3-fluoropyridin-2-yl]ethyl]amino]carbonyl)cyclopropane 669067-42-9P, (R)-1-((Trifluoromethyl)carbonyl)amino)-1-[[1-[5-[2-(ethoxy)-3-(fluoro)-5-(chlorophenyl)-3-chloropyridin-2-yl]ethyl]amino]carbonyl)cyclopropane 669067-43-0P 669067-44-1P, (R)-1-[(1,2,5-Thiadiazol-3-yl)carbonyl]amino)-1-[[1-[5-[2-(ethoxy)-3-


(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-46-3P,  
(R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(2,2,2-trifluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-53-2P,  
(R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(2,2-difluoroethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-54-3P,  
(R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(ethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-56-5P, (R)-1-[(Isoxazol-5-yl)carbonyl]amino]-1-[[1-[2-(2,2-trifluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-57-6P  
669067-58-7P, (R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(ethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-59-8P,  
(R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(2,2-difluoroethoxy)-3-(fluoro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-60-1P,  
(R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(2,2,2-trifluoroethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-62-3P,  
(R)-1-[(Isoxazol-5-yl)carbonyl]amino]-1-[[1-[5-[2-(2,2-difluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]pyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-64-5P, (R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(ethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-65-6P,  
(R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(2,2-difluoroethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-66-7P,  
(R)-1-[(Isoxazol-5-yl)carbonyl]amino]-1-[[1-[5-[2-(2,2-difluoroethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-67-8P,  
(R)-1-[(Isoxazol-5-yl)carbonyl]amino]-1-[[1-[5-[2-(ethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-68-9P, (R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(2,2,2-trifluoroethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-70-3P,  
(R)-1-[(Isoxazol-5-yl)carbonyl]amino]-1-[[1-[5-[2-(2,2,2-trifluoroethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-71-4P,  
(R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(2,2-difluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-72-5P,  
(R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(cyclopropyl)oxy]-3-(fluoro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-73-6P,  
(R)-1-[(Isoxazol-3-yl)carbonyl]amino]-1-[[1-[5-[2-(2,2-difluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-75-8P,  
(R)-1-[(Isoxazol-5-yl)carbonyl]amino]-1-[[1-[5-[2-(ethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-76-9P, (R)-1-[(Isoxazol-5-yl)carbonyl]amino]-1-[[1-[5-[2-(2,2-difluoroethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-77-0P,  
(R)-1-[(Isoxazol-5-yl)carbonyl]amino]-1-[[1-[5-[2-(2,2,2-trifluoroethoxy)-3-(chloro)-5-(chlorophenyl)-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-biaryl methylaminocycloalkanecarboxamide as bradykinin B1


antagonists)  
RN 669066-85-7 CAPLUS

CN Cyclopropanecarboxamide, N-[(3-chloro-5-[3,5-dichloro-2-(2,3-difluoropropoxy)phenyl]-2-pyridinyl)methyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)




RN 669066-86-8 CAPLUS

CN Cyclopropanecarboxamide, N-[(5-[3,5-dichloro-2-(2,3-difluoropropoxy)phenyl]-2-pyridinyl)methyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)



RN 669066-87-9 CAPLUS


CN Carbonic acid, 2-fluoro-6-[5-fluoro-6-[[[(1-[(trifluoroacetyl)amino]cyclopropyl)carbonyl]amino)methyl]-3-pyridinyl]phenyl methyl ester (9CI) (CA INDEX NAME)



RN 669067-11-2 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(difluoromethoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-15-6 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-5-[3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-17-8 CAPLUS


CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(2,3-difluoropropoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-18-9 CAPLUS  
CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(2,3-difluoropropoxy)-3-fluoroethyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

## Absolute stereochemistry.




RN 669067-19-0 CAPLUS  
CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(2,2-difluoroethoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]-  
(CA INDEX NAME)

## Absolute stereochemistry.



RN 669067-39-4 CAPLUS  
CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(5-chloro-2-ethoxy-3-fluorophenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


## Absolute stereochemistry.



RN 669067-40-7 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(2-fluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-42-9 CAPLUS


CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(5-chloro-2-ethoxy-3-fluoro-2-pyridinyl)ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-43-0 CAPLUS  
CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-(5-chloro-2-ethoxy-3-fluorophenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-44-1 CAPLUS  
CN 1,2,5-Thiadiazole-3-carboxamide, N-[1-[(1R)-1-[3-chloro-5-(5-chloro-2-ethoxy-3-fluorophenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 669067-46-3 CAPLUS  
CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-53-2 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-chloro-2-(2,2-difluoroethoxy)-5-fluorophenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-54-3 CAPLUS


CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(3-chloro-2-ethoxy-5-fluorophenyl)-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-56-5 CAPLUS  
CN 5-Isoxazolecarboxamide, N-[1-[[[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-57-6 CAPLUS  
CN Cyclopropanecarboxamide, N-[1-[[[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2,2-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 669067-58-7 CAPLUS  
CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(2-ethoxy-3,5-difluorophenyl)-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-59-8 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[2-(2,2-difluoroethoxy)-3,5-difluorophenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-60-1 CAPLUS


CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-chloro-5-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-62-3 CAPLUS  
CN 5-Isoazolecarboxamide, N-[1-[(1R)-1-[5-[5-chloro-2-(2,2-difluoroethoxy)-3-fluorophenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-64-5 CAPLUS  
CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-ethoxyphenyl)-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 669067-65-6 CAPLUS  
CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-(2,2-difluoroethoxy)phenyl)-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-66-7 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-[3-chloro-2-(2,2-difluoroethoxy)-5-fluorophenyl]-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-67-8 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-(3-chloro-2-ethoxy-5-fluorophenyl)-2-pyridinyl]ethyl]amino]carbonylcyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-68-9 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-70-3 CAPLUS

CN 5-Isoazolecarboxamide, N-[(1R)-1-[3-chloro-5-[3-chloro-5-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-71-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[5-chloro-2-(2,2-difluoroethoxy)-3-fluorophenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-72-5 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[2-(cyclopropyloxy)-3,5-difluorophenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-73-6 CAPLUS


CN 3-Isoxazolecarboxamide, N-[(1R)-1-[3-chloro-5-[5-chloro-2-(2,2-difluoroethoxy)-3-fluorophenyl]-2-pyridinyl]ethyl]amino]carbonyl)cyclopropyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-75-8 CAPLUS  
CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-ethoxyphenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-76-9 CAPLUS  
CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 669067-77-0 CAPLUS  
CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:971837 CAPLUS  
 DOCUMENT NUMBER: 140:27621  
 TITLE: Preparation of 1,2-diamido cycloalkyl sodium channel blockers  
 INVENTOR(S): Fisher, Michael H.; Li, Chunshi; Liang, Jun; Meinke, Peter T.; Ok, Dong; Parsons, William H.; Shao, Pengcheng Patrick; Tyagarajan, Sriram  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 133 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE      | APPLICATION NO. | DATE           |
|------------------------|--|-----------|-----------------|----------------|
| WO 2003101381          | A2   | 20031211  | WO 2003-US16335 | 20030523 <--   |
| WO 2003101381          | A3   | 20040212  |                 |                |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |           |                 |                |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |           |                 |                |
| AU 2003237224          | A1   | 20031219  | AU 2003-237224  | 20030523 <--   |
| PRIORITY APPLN. INFO.: |  |           | US 2002-383832P | P 20020529 <-- |
|                        |  |           | WO 2003-US16335 | W 20030523 <-- |
| OTHER SOURCE(S): GI    | MARPAT   | 140:27621 |                 |                |



**AB** The patent relates to the preparation of 1,2-diamido cycloalkyl compds. I ( $X = \text{Ph}$ , pyridyl, thiienyl, etc.;  $R1 = \text{H}$ , C1-6 alkyl;  $R2 = \text{C}0\text{-6 alkyl-Ph}$ , C1-6 alkylthiazolyl, C1-6 alkylthiazolyl, etc.;  $R1R2 = 5$  or 6 membered ring;  $E = \text{C1-6 alkyl}$ ;  $R3 = \text{C}0\text{-6 alkyl}$ ;  $A = \text{CnH}2n$ ;  $B = \text{CmH}2m$ ;  $n, m = 0\text{-}3$ ;  $n + m = 1\text{-}3$ ;  $R4, R5 = \text{C}0\text{-6 alkyl}$ , OH, halo, etc.). The 1,2-diamido cycloalkyl compds. are useful as: sodium channel blockers; pharmaceutical compns. that include an effective amount of the aryl-link-aryl thiazolidindione and aryl-link-aryl oxazolidinedione compds. and a pharmaceutically acceptable carrier; and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as irritable bowel syndrome, Crohn's disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar disease, and tachyarrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compds., either alone, or in combination with one or more therapeutically active compds. Thus, trans-1-(RS)-[4-(2-aminoethylphenyl)]benzylaminocarbonyl-2-(SR)-benzylaminocarbonylcyclopentane was prepared by reacting a mixture comprising 1-(RS)-[4-(2-aminoethylphenyl)]benzylaminocarbonyl-2-(SR)-carboxycyclopentane, N-hydroxybenzotriazole, diisopropylethylamine, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate, and benzylamine wherein 1-(RS)-[4-(2-aminoethylphenyl)]benzylaminocarbonyl-2-(SR)-carboxycyclopentane was prepared from the reaction of trans-DL-cyclopentane dicarboxylic acid and 4-(2-aminoethylphenyl)benzylamine.

**IT** 632338-84-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,2-diamido cycloalkyl sodium channel blockers)

RN 632338-84-2 CAPLUS

CN 1,2-Cyclopentanedicarboxamide, N1-methyl-N2-[{4-(trifluoromethoxy)phenyl]methyl]-N1-[{5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



```
=> fil stnguide
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY        SESSION
FULL ESTIMATED COST          41.23         220.26
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE      TOTAL
                                                ENTRY        SESSION
CA SUBSCRIBER PRICE           -5.60          -5.60
```

FILE 'STNGUIDE' ENTERED AT 13:30:10 ON 24 DEC 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Dec 19, 2008 (20081219/UP).

```
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY        SESSION
FULL ESTIMATED COST          0.30          220.56
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE      TOTAL
                                                ENTRY        SESSION
CA SUBSCRIBER PRICE           0.00          -5.60
```

STN INTERNATIONAL LOGOFF AT 13:33:00 ON 24 DEC 2008